Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients

Pharmacogenomics

Volumn 12, Issue 10, 2011, Pages 1397-1406

  Chen, Chia Hui ^a,b   Wang, Sheng Chang ^a   Tsou, Hsiao Hui ^c   Ho, Ing Kang ^a   Tian, Jia Ni ^a   Yu, Cheng Jou ^d,e   Hsiao, Chin Fu ^f   Chou, Sun Yuan ^b   Lin, Yen Feng ^f,g   Fang, Kai Chi ^g   Huang, Chieh Liang ^h   Su, Lien Wen ⁱ   Fang, Yong Chun ⁱ   Liu, Ming Lun ^j   Lin, Keh Ming ^k   Hsu, Ya Ting ^l   Liu, Shu Chih ^m   Chen, Andrew C H ^m   Liu, Yu Li ^m  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Taoyuan Mental Hospital   (Taiwan)

^e EN CHU KONG HOSPITAL   (Taiwan)

^f FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

^h CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ TAIPEI CITY HOSPITAL   (Taiwan)

^j Wei Gong Memorial Hospital   (Taiwan)

^k Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^l CHINA MEDICAL UNIVERSITY   (Taiwan)

^m NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

betel nut; clinical opioid withdrawal scale; CYP3A4; heroin addiction; methadone; SNP

Indexed keywords

AMITRIPTYLINE; ATAZANAVIR; BIOLOGICAL MARKER; CIMETIDINE; CIPROFLOXACIN; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DRUG METABOLITE; FLUOXETINE; ISOENZYME; METHADONE; OXCARBAZEPINE; PREDNISOLONE; RITONAVIR; SERTRALINE;

ADULT; ALLELE; ARTICLE; BETEL NUT; CHINESE; CLINICAL ASSESSMENT; CONSTIPATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG RESPONSE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART RATE; HEROIN DEPENDENCE; HUMAN; LIBIDO DISORDER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; STATISTICAL MODEL; TAIWAN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; AMITRIPTYLINE; ARECA; BIOMARKERS, PHARMACOLOGICAL; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC ASSOCIATION STUDIES; HEART RATE; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SUBSTANCE WITHDRAWAL SYNDROME;

ARECA CATECHU; PIPER BETEL;

EID: 80054923521     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.103     Document Type: Article

References (36)

1. Mattick R, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 3, 1-17 (2009).
2. Metzger D, Zhang Y. Drug treatment as HIV prevention. Expanding treatment options. Curr. HIV/AIDS Rep. 7(4), 220-225 (2010).
3. Kelly T, Doble P, Dawson M. Chiral analysis of methadone and its major metabolites (EDDP and EMDP) by liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 814(2), 315-323 (2005). (Pubitemid 40091650)
4. Crettol S, Deglon JJ, Besson J et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 80(6), 668-681 (2006). (Pubitemid 44920225)
5. Kristensen K, Blemmer T, Angelo H et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther. Drug Monit. 18(3), 221-227 (1996). (Pubitemid 26159571)
6. Chang Y, Fang WB, Lin SN, Moody DE. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin. Pharmacol. Toxicol. 108(1), 55-62 (2011).
7. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108(3), 363-374 (2008). (Pubitemid 351304229)
8. Crettol S, Deglon J, Besson J et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78(6), 593-604 (2005). (Pubitemid 41773635)
9. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16(1), 36-44 (2004). (Pubitemid 37532283)
10. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro. Drug Metab. Disposition 31(6), 742-747 (2003).
11. Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 101(3), 158-168 (2009).
12. Prost F, Thormann W. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (supersomes): application to the chiral metabolism of mephenytoin and methadone. Electrophoresis 24(15), 2577-2587 (2003). (Pubitemid 38089045)
13. Qiu X, Jiao Z, Zhang M et al. Association of MDR1, CYP3A4* 18B, and CYP3A5* 3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur. J. Clin. Pharmacol. 64(11), 1069-1084 (2008).
14. Tsai MH, Lin KM, Hsiao MC et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11(4), 537-546 (2010).
15. Nelson B, Heischober B. Betel nut: a common drug used by naturalized citizens from India, Far East Asia, and the South Pacific Islands. Ann. Emergency Med. 34(2), 238-243 (1999). (Pubitemid 29361875)
16. Tung T, Chiu Y, Chen L, Wu H, Boucher B, Chen T. A population-based study of the association between areca nut chewing and Type 2 diabetes mellitus in men (Keelung Community-based Integrated Screening programme No. 2). Diabetologia 47(10), 1776-1781 (2004). (Pubitemid 40022413)
17. Marsden J, Farrell M, Bradbury C et al. Development of the treatment outcomes profile. Addiction 103(9), 1450-1460 (2008).
18. Wesson D, Ling W. The clinical opiate withdrawal scale (COWS). J. Psychoactive Drugs 35(2), 253-259 (2003). (Pubitemid 36927370)
19. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised Edition. Guy W (Ed.). Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, MD, USA (1976).
20. American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology 123(4), 1364-1366 (2002).
21. Wang SC, Ho IK, Wu SL et al. Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients. Biomed. Chromatogr. 24(7), 782-788 (2010).
22. Wen S, Wang H, Ding Y, Liang H, Wang S. Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray. Genet. Test. 8(4), 411-416 (2004). (Pubitemid 40083107)
23. Yuan H, Chiou J, Tseng W et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 34, W635-W641 (2006). (Pubitemid 44529848)
24. Rodi C, Darnhofer-Patel B, Stanssens P, Zabeau M, van den Boom D. A strategy for the rapid discovery of disease markers using the MassARRAY system. BioTechniques 32, S62-S69 (2002). (Pubitemid 34615026)
25. Tost J, Gut I. Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin. Biochem. 38(4), 335-350 (2005). (Pubitemid 40342864)
26. Rice JA. Mathematical statistics and data analysis (2nd Edition). Duxbury Press, Belmont, CA, USA (1995).
27. Merchant KA. Budgeting and the propensity to create budgetary slack. Account. Org. Soc. 10(2), 201-210 (1985).
28. Barrett J, Fry B, Maller J, Daly M. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005). (Pubitemid 40202029)
29. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73(5), 1162-1169 (2003). (Pubitemid 37414228)
30. Eap C, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41(14), 1153-1193 (2002). (Pubitemid 35398691)
31. Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol. Res. 50(6), 551-559 (2004).
32. Friedland G, Andrews L, Schreibman T et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 19(15), 1635-1641 (2005). (Pubitemid 41502676)
33. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin. Pharmacol. Ther. 76(3), 250-269 (2004). (Pubitemid 39221799)
34. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med. 9(3), 315-344 (2008). (Pubitemid 351467888)
35. Gore M, Sadosky A, Leslie D, Sheehan AH. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: a study using the UK and Germany Mediplus databases. Pain Pract. 8(4), 253-262 (2008).
36. Wang SC, Ho IK, Tsou HH et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J. Clin. Psychopharmacol. 31(4), 463-469 (2011).